Zydus Lifesciences acquires rights to market MonoFerric injections in India, Nepal

09 Sep 2022 Evaluate

Zydus Lifesciences has acquired rights to market MonoFerric (iron isomaltoside) injections in India and Nepal from Denmark based Pharmacosmos A/S. MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron (up to 20 mg/kg bodyweight) developed to reduce the number of infusions required to achieve iron correction with an excellent safety profile. MonoFerric is indicated for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.

MonoFerric is available in over 30 countries including US and Europe and over 28 million doses have been administered since launch.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

875.95 -5.15 (-0.58%)
20-Jan-2026 14:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.65
Dr. Reddys Lab 1175.85
Cipla 1380.80
Zydus Lifesciences 875.95
Lupin 2170.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×